BioLineRx Ltd. (NASDAQ:BLRX – Get Free Report) shares crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.56 and traded as high as $1.62. BioLineRx shares last traded at $1.57, with a volume of 483,457 shares.
Analysts Set New Price Targets
A number of research analysts have recently commented on BLRX shares. StockNews.com started coverage on shares of BioLineRx in a report on Thursday, October 5th. They issued a “sell” rating for the company. HC Wainwright increased their target price on shares of BioLineRx from $19.00 to $21.00 and gave the stock a “buy” rating in a report on Friday, September 15th.
BioLineRx Price Performance
BioLineRx (NASDAQ:BLRX – Get Free Report) last posted its quarterly earnings results on Wednesday, August 30th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.14). During the same period in the previous year, the company posted ($0.16) earnings per share. As a group, equities research analysts predict that BioLineRx Ltd. will post -0.83 EPS for the current fiscal year.
Hedge Funds Weigh In On BioLineRx
A number of institutional investors and hedge funds have recently modified their holdings of the business. Renaissance Technologies LLC lifted its holdings in shares of BioLineRx by 49.1% in the 3rd quarter. Renaissance Technologies LLC now owns 68,222 shares of the biotechnology company’s stock worth $63,000 after purchasing an additional 22,478 shares in the last quarter. LPL Financial LLC lifted its stake in BioLineRx by 152.7% during the 4th quarter. LPL Financial LLC now owns 117,710 shares of the biotechnology company’s stock valued at $69,000 after acquiring an additional 71,134 shares in the last quarter. Geneos Wealth Management Inc. lifted its stake in BioLineRx by 72.3% during the 3rd quarter. Geneos Wealth Management Inc. now owns 40,500 shares of the biotechnology company’s stock valued at $74,000 after acquiring an additional 17,000 shares in the last quarter. Envestnet Asset Management Inc. bought a new position in BioLineRx during the 1st quarter valued at $88,000. Finally, Atria Wealth Solutions Inc. bought a new position in BioLineRx during the 1st quarter valued at $178,000. 2.01% of the stock is currently owned by institutional investors.
BioLineRx Company Profile
BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia.
- Five stocks we like better than BioLineRx
- 3 Best Fintech Stocks for a Portfolio Boost
- A bullish storm is brewing for cloud stocks
- How to Invest in the Healthcare Sector
- Is Extreme Networks’ forecast a sign of industry woes?
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Profits come after ignorance Is highest: A PayPal story
Receive News & Ratings for BioLineRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx and related companies with MarketBeat.com's FREE daily email newsletter.